Steven Chance for Oxford Brain Diagnostics, Ltd
Oxford Brain Diagnostics Ltd
Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases. The CDM® software device can be used as an adjunct to other diagnostics evaluations, intended to predict conversion from Mild Cognitive Impairment to Alzheimer’s Disease in patients previously diagnosed with MCI.